PROCEPT BioRobotics is a surgical robotics company developing next-generation solutions to treat prostate disease. PROCEPT has developed Aquablation® therapy, a novel and disruptive treatment for benign prostatic hyperplasia (BPH) that provides significant symptom relief with less risk of side effects that impact their quality of life compared to the surgical gold-standard TURP. The company’s first product, the AquaBeam® Robotic System, is the world’s first surgical robot providing autonomous tissue removal for the safe and effective treatment of BPH, independent of prostate anatomy or surgeon experience.
Brands: AQUABEAM® Robotic System for Aquablation® therapy